RxDoctor Payments Data

Alice Lockman

Family · Montgomery, WVNPI 1487960407

Payments from drug & device makers

$4,150in general payments, 2019–2025

Across 153 payments — averaging $27.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novo Nordisk$525
  • AbbVie$359
  • Lilly USA, LLC$326
  • Dexcom, Inc.$278
  • Viiv Healthcare Company$249
  • plus $332 from 13 others

What the payments were for

  • Food & beverage$4,10099%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,150 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$3,752
Medicare patients
29
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$93,181
OzempicSemaglutide52$79,179
TrulicityDulaglutide19$43,874
MounjaroTirzepatide20$41,482
Tresiba Flextouch U-200Insulin Degludec43$37,519
Novolog FlexpenInsulin Aspart63$19,285
JanuviaSitagliptin Phosphate13$19,029
Tresiba Flextouch U-100Insulin Degludec30$16,318
SynthroidLevothyroxine Sodium117$13,511
Insulin Aspart FlexpenInsulin Aspart16$7,382
Humalog Kwikpen U-100Insulin Lispro16$6,429
Novolin N FlexpenInsulin Nph Human Isophane19$6,380
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$6,061
Nano 2nd Gen Pen NeedlePen Needle, Diabetic24$2,712
Ultra-Fine Short Pen NeedlePen Needle, Diabetic19$2,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$38$93,18168 claims
Lilly USA, LLCTrulicity, Mounjaro$326$85,35639 claims
Novo NordiskOzempic$525$79,17952 claims
AbbVieSynthroid$359$13,511117 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$1,296103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in Montgomery

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →